Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia

Leukemia and Lymphoma

Volumn 47, Issue 1, 2006, Pages 81-88

  Alimoghaddam, Kamran ^a   Shariftabrizi, Ahmad ^a   Tavangar, Mohammad ^b   Sanaat, Zohreh ^a   Rostami, Shahrbanoo ^a   Jahani, Mohammad ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyeolocytic leukemia; Angiogenesis; Arsenic trioxide; Bone marrow vascular density; Drug toxicity; Survival rate

Indexed keywords

ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; CD31 ANTIGEN; DAUNORUBICIN; DEXAMETHASONE; POTASSIUM; VON WILLEBRAND FACTOR;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; COXSACKIE VIRUS INFECTION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSPNEA; ECG ABNORMALITY; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; LEUKOCYTOSIS; LIVER TOXICITY; METABOLIC DISORDER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THORAX PAIN; TUMOR DIFFERENTIATION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ARSENICALS; BONE MARROW; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OXIDES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 30844467318     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500300373     Document Type: Article

References (32)

1. Warrell, R, Jr and de The, H and Wang, Z and Degos, L. (1993) Acute promyelocytic leukemia New England Journal of Medicine, 329, pp. 177 - 189.
2. Rodighiero, F and Avvisati, G and Castaman, G and Mandelli, F. (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients Blood, 75, pp. 2112 - 2117.
3. Shen, Z and Chen, G and Ni, J and Li, X and Xiong, S and Qiu, Q and (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: Clinical efficacy and pharmacokinetics in relapsed patients Blood, 89, pp. 3354 - 3360.
4. Au, W and Lie, A and Chim, C and Liang, R and Ma, S and Chan, C and (2003) Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia Oncology, 14, pp. 752 - 757.
5. Soignet, S and Frankel, S and Douer, D and Tallman, M and Kantarjian, H and Calleja, E and (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia Journal of Clinical Oncology, 19, pp. 3852 - 3860.
6. Soignet, S and Maslak, P and Wang, Z and Jhanwar, S and Calleja, E and Dardashti, L and (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide New England Journal of Medicine, 339, pp. 1341 - 1348.
7. Niu, C and Yan, H and Yu, T and Sun, H and Liu, J and Li, X and (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients Blood, 94, pp. 3315 - 3324.
8. Mathews, V and Balasubramanian, P and Shaji, R and George, B and Chandy, M and Srivastava, A. (2002) Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia American Journal of Hematology, 70, pp. 292 - 299.
9. Hussong, J and Rodgers, G and Shami, P. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia Blood, 95, pp. 309 - 313.
10. Aguayo, A and Kantarjian, H and Manshouri, T and Gidel, C and Estey, E and Thomas, D and (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Blood, 96, pp. 2240 - 2245.
11. Padro, T and Ruiz, S and Bieker, R and Burger, H and Steins, M and Kienast, J and (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia Blood, 95, pp. 2637 - 2644.
12. Kini, A and Peterson, L and Tallman, M and Lingen, M. (2001) Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid Blood, 97, pp. 3919 - 3924.
13. Foss, B and Mentzoni, L and Bruserud, O. (2001) Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts Journal of Hematotherapy Stem Cell Research, 10, pp. 81 - 93.
14. Roboz, G and Dias, S and Lam, G and Lane, W and Soignet, S and Warrell, R, Jr and (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis Blood, 96, pp. 1525 - 1530.
15. van Dongen, J and Macintyre, E and Gabert, J and Delabesse, E and Rossi, V and Saglio, G and (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia Leukemia, 13, pp. 1901 - 1928.
16. Cassinat, B and Chevret, S and Zassadowski, F and Balitrand, N and Guillemot, I and Menot, M and (2001) In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: A novel indicator of poor patient outcome Blood, 98, pp. 2862 - 2864.
17. Imaizumi, M and Suzuki, H and Yoshinari, M and Sato, A and Saito, T and Sugawara, A and (1998) Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia Blood, 92, pp. 374 - 382.
18. Borrow, J and Goddard, A and Gibbons, B and Katz, F and Swirsky, D and Fioretos, T and (1992) Diagnosis of acute promyelocytic leukaemia by RT-PCR detection of PML-RARA and RARA-PML fusion tran-scripts British Journal of Haematology, 82, pp. 529 - 540.
19. Huang, W and Sun, G and Li, X and Cao, Q and Lu, Y and Jang, G and (1993) Acute promyelocytic leukemia: Clinical relevance of two major PML-RARa isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse Blood, 82, pp. 1264 - 1269.
20. Vahdat, L and Maslak, P and Miller, W, Jr and Eardley, A and Heller, G and Scheinberg, D and (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-a isoform, and CD13 expression in patients treated with all-trans retinoic acid Blood, 84, pp. 3843 - 3849.
21. Fukutani, H and Naoe, T and Ohno, R and Yoshida, H and Miyawaki, S and Shimazaki, C. (1995) Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia, 9, pp. 1478 - 1482.
22. Gallagher, R and Willman, C and Slack, J and Anderson, J and Li, Y and Viswanatha, D and (1997) Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study Blood, 90, pp. 1656 - 1663.
23. Zhou, J and Meng, R and Yang, B. (2004) Comparing two arsenic trioxide administration methods in APL therapy Chinese Medicine Journal (England), 117, pp. 1411 - 1413.
24. Perez-Atayde, A and Sallan, S and Tedrow, U and Connors, S and Allred, E and Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia American Journal of Pathology, 150, pp. 815.
25. Pule, M and Gullmann, C and Dennis, D and McMahon, C and Jeffers, M and Smith, O. (2002) Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance British Journal of Haematology, 118, pp. 991 - 998.
26. Reddy, V and Moreb, J. (2000) Prognostic correlation of increased angiogenesis in acute myeloid leukemia with cytogenetics Blood, 96, pp. 1617 - 1618.
27. Pule, M and Gullmann, C and Dennis, D and McMahon, C and Jeffers, M and Smith, O. (2002) Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance British Journal of Haematology, 118, pp. 991 - 998.
28. Korkolopoulou, P and Viniou, N and Kavantzas, N and Patsouris, E and Thymara, I and Pavlopoulos, P and Terpos, E and Stamatopoulos, K and Plata, E and Anargyrou, K and Androulaki, A and Davaris, P and Yataganas, X. (2003) Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: A morphometric study Leukemia, 17, pp. 89 - 97.
29. Browder, T and Butterfield, C and Kräling, B and Shi, B and Marshall, B and O'Reilly, M and (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Research, 60, pp. 1878 - 1886.
30. Lew, Y and Brown, S and Griffin, R and Song, K and Kim, J. (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown Cancer Research, 59, pp. 6033 - 6037.
31. Griffin, R and Lee, S and Rood, K and Stewart, M and Lyons, J and Lew, Y and Park, H and Song, C. (2000) Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors Neoplasia, 2, pp. 555 - 560.
32. Shen, Z and Shen, J and Chen, M and Wu, X and Wu, M and Zeng, Y. (2003) The inhibition of growth and angiogenesis in heterotransplanted esophageal carcinoma via intratumoral injection of arsenic trioxide Oncology Reports, 10, pp. 1869 - 1874.